Mitochondrial fatty acid oxidation (FAO) represents a normal metabolic response to increased energy demands during periods of fasting, febrile illness, or muscular exertion. FAO is a complex pathway involving activation of free fatty acids to acyl-CoA species, transport into mitochondria, and cyclic oxidation to break the longchain fatty acids into acetyl-CoA and a two-carbon chainshortened acyl-CoA, which is then recycled. Acetyl-CoA is used in the Krebs cycle and in liver as a substrate for ketogenesis (1 ) . Measurement of FAO flux in cultured cells provides valuable information about the integrity of the enzymes and transporters involved in FAO at all stages. Clinical indications for the measurement of FAO flux in skin fibroblasts include fatty acid oxidation enzyme defects, unexplained myopathies, cardiomyopathies, hypoglycemia, liver disease, sudden unexplained infant death, and hypoketotic hypoglycemia. FAO flux is typically measured by monitoring the conversion of radiolabeled fatty acids to carbon dioxide and water. Labeling can be with 14 C with final analysis of the rate of production of 14 CO 2 , or with 3 H and analysis of production of 3 H 2 O (2, 3 ). Palmitic acid (C16) is used to detect long-chain defects, including deficiencies in very long chain acyl-CoA dehydrogenase, long-chain l-3-hydroxy acyl-CoA dehydrogenase, long-chain 3-keto acyl-CoA thiolase, carnitine/acylcarnitine translocase, carnitine pamitoyltransferase 1, and carnitine pamitoyltransferase 2. Myristic acid (C14) is used to detect defects in mediumchain FAO, such as medium-chain acyl-CoA dehydrogenase deficiency. We use tritiated fatty acids labeled in the (9,10) position. The assay will not detect defects in carnitine palmitoyl transferase 1B; short-chain FAO defects, including short-chain acyl-CoA dehydrogenase and short-chain l-3-hydroxy acyl-CoA dehydrogenase; and short-chain-3-keto acyl-CoA thiolase deficiencies.
Historically, patient samples have been compared with batch controls, and a reference interval was not established for this assay. In the present study we have assigned a reference interval for the assay, using FAO flux results from triplicate assays performed on 1000 fibroblast samples. These samples were derived from individuals with clinical signs indicating impaired energy metabolism but with apparently normal FAO compared with data obtained from patients with well-characterized, genetically confirmed FAO defects. Assigning a reference interval is critical for a clinically reportable assay because it simplifies the interpretation of the results and provides a clear definition of disease vs nondisease.
The FAO flux assay consists of measurement of FAO flux in fibroblasts obtained from one T-25 flask for each patient, typically with fewer than eight passages of culture. Fibroblasts are trypsinized and resuspended in 12-36 mL of DMEM (cat. no. 11885-084; Gibco Life Technologies) containing 1 g/L glucose and supplemented with 100 mL/L fetal calf serum (cat. no. 26140-053; Gibco Life Technologies). From this suspension, 1 mL is transferred to 2 wells in each of five 24-well tissue culture plates. Three nondisease control fibroblast and two disease control fibroblast lines are simultaneously seeded in the same plate along with one to six additional patient lines. Cultures are placed in an incubator to allow the fibroblasts to attach and then grow for 48 h at 37°C, in 5% CO 2 , 100% humidity (CO 2 Incubator; NUAIRE). The cells are then washed with phosphate-buffered saline (pH 6.9) and incubated with preincubation medium (Krebs Ringer Bicarbonate Medium; cat. no. K-4002; Sigma) containing 0.5 g/L bovine serum albumin (fatty-acid free, cat. no. A-6003; Sigma) in the assay plates or with inhibitor medium [preincubation medium ϩ FAO inhibitors consisting of 0.45 mmol/L malonyl-CoA (cat. no. M-4263; Sigma), 0.02 mmol/L glybenclamide (cat. no. G-0639; Sigma), 0.79 mmol/L 3-mercaptoproprionic acid (cat. no. M-6750; Sigma), and 2.74 mmol/L glucose (cat. no. G-5767; Sigma) in a buffer containing 1.0 g/L bovine serum albumin] in the blank plates for 1 h. The fifth plate, used for measuring protein, is washed as the others, but 50 L of 1 mol/L NaOH is added to each well of this plate and the plate is incubated at 37°C, 100% humidity for 2 h. After incubation, 50 L of 1 mol/L HCl is added to neutralize the samples, and both wells from the same cell line are combined for protein measurement by the Lowry method (4 ). After preincubation, the medium is removed, and 200 L of tritiated myristate or palmitate (incubation medium, 110 mol/L fatty acid, 16.7 Ci/mL [ 3 H]fatty acid, and 0.5 g/L bovine serum albumin in phosphatebuffered saline, pH 6.9) is added to each well of the assay plates and incubated. Blank plates are incubated with [ 3 H]palmitate or [ 3 H]myristate incubation medium containing the FAO inhibitors. This provides a blank reading for nonmitochondrial FAO, which is presumed to be mostly peroxisomal (5) (6) (7) (8) . The plates are returned to the incubator and incubated at 37°C in 5% CO 2 , 100% humidity for 2-3 h, after which the incubation medium is transferred to columns containing ϳ2.9 mL of Dowex-1 ion-exchange resin (cat. no. 1X8-200; Sigma), which has been charged with 1.0 mol/L NaOH and washed with MilliQ water until the eluate is the same pH as the wash water. This binds the nonmetabolized fatty acids and allows the tritiated water produced by ␤-oxidation to pass through. The plates are washed with 300 L of phosphatebuffered saline (pH 6.9), and the wash is passed through the columns, which are subsequently washed with 2 mL of water. The entire eluate is collected in a mini scintillation vial to which 4 mL of scintillation cocktail (ScintiVerse II; cat, no. SX 12-4; Fisher Scientific) is added, and the vial is counted in a Beckmann LS 6500 liquid scintillation counter.
The rate of FAO is calculated by the following formula:
Sample CPM Ϫ Inhibited CPM Total CPM/fatty acid concentration ϫ (time, in min) (mg protein/well) ϭ
The oxidation rates are compared between nondisease and disease controls. Oxidation rates that are consistently Ͻ70% of the nondisease controls in triplicate analyses are flagged as low.
In the present study, we used the FAO values from nondisease control fibroblasts over a period of 10 years to determine reference intervals, which are shown in Fig. 1 , A and B. We calculated the central 95% intervals with the EP Evaluator 5 series, using the nonparametric method (NCCLS C28-A) and transformed parametric data. Palmitic and myristic acid oxidation showed nongaussian distribution of data within the 95% confidence interval (Fig. 1, A and B) . In the transformed parametric method, the scale was changed to fit the data to a gaussian (n ϭ 1000); median, 38 pmol ⅐ min Ϫ1 ⅐ (mg protein) Ϫ1 . True gaussian distribution is superimposed for comparison with original data. (B), mean (SD) 27 (19) pmol ⅐ min Ϫ1 ⅐ (mg protein) Ϫ1 (n ϭ 1000); median, 23 pmol ⅐ min Ϫ1 ⅐ (mg protein)
Ϫ1 . True gaussian distribution is superimposed for comparison with original data. (C), the lower horizontal line of the scatter plot represents 70% of mean normal activity and our arbitrarily defined cutoff value. The upper horizontal line represents 70 -80% residual activity and equivocal results. The numbers of confirmed patients are shown in parentheses below the x axis (see Table 2 in the inline Data Supplement). ࡗ, palmitate (mean, ); f, myristate (mean, Ⅺ). CPT1, carnitine pamitoyltransferase 1 deficiency; CPT2, carnitine pamitoyltransferase 2 deficiency; GA2, glutaric acidemia type 2; LCHAD, long-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency; MCAD, medium-chain acyl-CoA dehydrogenase deficiency; SCHAD, short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency; TFP, trifunctional protein defect; VLCAD, very long chain acyl-CoA dehydrogenase deficiency. distribution, and the mean (Ϯ2 SD) was computed and then converted to the original units. True gaussian distributions are shown superimposed in panels A and B of Fig. 1 for comparison (1, 9, 10 ) . Data from patients with several well-characterized FAO defects are shown in Fig. 1C . The lower horizontal line represents the chosen cutoff as a percentage of the normal FAO rate, and the upper line indicates the zone in which the results are equivocal. This scatter plot shows that patients with Ͻ70% of the normal oxidation rate are clearly identified as abnormal. However, the scattered data points in the range of 70 -80% of normal are without a clear indication of a deficiency. These data show a small overlap with the lower end of the reference interval but indicate that most patients would be identified by this reference interval. Several patients with FAO values in the lower end of the reference interval had mutations with high residual activity, which would predict higher flux. For example, the case of carnitine pamitoyltransferase 1 deficiency with the highest residual flux is the patient who was reported to be homozygous for the mild P479L mutation (11 ) and adult-onset disease.
The major advantage of the FAO flux assay is that it is the only assay that can test the true flux through the FAO pathway, whereas the alternative method using tandem mass spectrometry can accurately verify the exact site of an enzyme defect, making the two approaches complementary. However, in our experience, many patients in whom enzyme activities are within the reference interval have abnormal flux. These patients are currently characterized as having FAO defects of unknown etiology and may have defects of a nonenzymatic nature. The FAO flux assay is the only assay that can diagnose these patients at present.
